As for disclosing, in regard to remedy the anti- pulse tube formation chemical compound in the effective quantity and at least the molecular weight of 2000, it is suspended material inside the effective pharmacy composition with form of the eye which includes the polyethylene glycol which at least possesses the molecular weight of 3000 more desirably. That composition is more desirable, for example obstacle of the eye (, the diabetes retina symptom, age increase characteristic yellow spot denaturation and the yellow spot edema, the grape membrane flame, and map condition atrophy) it is something for dealing with. In another execution form, for example (a) the active medicine (, anti- pulse tube formation chemical compound, anti- inflammation chemical compound, or the anti- blood vessel permeable medicine) (B) high-molecular quantity PEG of appropriate quantity (C) appropriate buffer (D) according to need the isotonic conversion medicine (E) slurrying medicine And (f) after including the surface active agent, the sclera vicinity (PJ) and around the eye (PO) compound ones of business are offered.開示するのは、治療上有効な量における抗脈管形成化合物および少なくとも2000の分子量、より好ましくは少なくとも3000の分子量を有するポリエチレングリコールを含む眼内用懸濁物の形態での有効な薬学的組成物である。その組成物は、より好ましくは、眼の障害(例えば、糖尿病網膜症、加齢性黄斑変性、黄斑浮腫、ブドウ膜炎、および地図状萎縮)の処置のためのものである。別の実施形態において、(a)活性薬剤(例えば、抗脈管形成化合物、抗炎症化合物、または抗血管透過性薬剤);(b)適切な量の高分子量PEG;(c)適切なバッファー;(d)必要に応じて等張化剤;(e)懸濁化剤;および(f)界面活性剤を含む後強膜近傍(PJ)および眼周囲(PO)用の調合物が提供される。
